Amylyx Pharmaceuticals (AMLX) EBIAT (2021 - 2025)
Historic EBIAT for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$34.4 million.
- Amylyx Pharmaceuticals' EBIAT rose 5270.41% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 4246.57%. This contributed to the annual value of -$301.7 million for FY2024, which is 71241.5% down from last year.
- According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' EBIAT is -$34.4 million, which was up 5270.41% from -$41.4 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' EBIAT registered a high of $22.1 million during Q2 2023, and its lowest value of -$118.8 million during Q1 2024.
- For the 5-year period, Amylyx Pharmaceuticals' EBIAT averaged around -$34.2 million, with its median value being -$35.9 million (2025).
- Its EBIAT has fluctuated over the past 5 years, first soared by 14082.71% in 2023, then tumbled by 765200.25% in 2024.
- Over the past 5 years, Amylyx Pharmaceuticals' EBIAT (Quarter) stood at -$28.3 million in 2021, then tumbled by 50.66% to -$42.7 million in 2022, then surged by 111.08% to $4.7 million in 2023, then crashed by 893.62% to -$37.5 million in 2024, then grew by 8.42% to -$34.4 million in 2025.
- Its last three reported values are -$34.4 million in Q3 2025, -$41.4 million for Q2 2025, and -$35.9 million during Q1 2025.